Evidence map›Paper›PMID 33236967›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2021

An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.

Andrew R Romeo, William M Rowles, Erica S Schleimer, Patrick Barba, Wan-Yu Hsu, Refujia Gomez, Adam Santaniello, Chao Zhao, Jennifer R Pearce, J B Jones and 6 more

Abstract read
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. The epidemiology, pathology and pathogenesis of MS: Therapeutic implications.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Remote Observational Research for Multiple Sclerosis: A Natural Experiment.Neurology(R) neuroimmunology & neuroinflammation · 2023
    Article
  8. Article
  9. Effects of melatonin on sleep disturbances in multiple sclerosis: A randomized, controlled pilot study.Multiple sclerosis journal - experimental, translational and clinical · 2021
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andrew R RomeoUCSF MS Epic Study Group.
William M RowlesUCSF MS Epic Study Group.
Erica S SchleimerUCSF MS Epic Study Group.ORCID 0000-0001-5040-6306
Patrick BarbaUCSF MS Epic Study Group.
Wan-Yu HsuUCSF MS Epic Study Group.
Refujia GomezUCSF MS Epic Study Group.
Adam SantanielloUCSF MS Epic Study Group.
Chao ZhaoUCSF MS Epic Study Group.
Jennifer R PearcePlain Language Health, San Francisco, CA, USA.ORCID 0000-0001-6766-6323
J B JonesSutter Health, Palo Alto Medical Foundation Research Institute, Walnut Creek, CA, USA.
Bruce C CreeUCSF MS Epic Study Group.
Stephen L HauserUCSF MS Epic Study Group.
Jeffrey M GelfandUCSF MS Epic Study Group.
Walter F StewartMedcurio Inc., Oakland, CA, USA.
Douglas S GoodinUCSF MS and Neuroinflammation Center, Weill Institute for Neurosciences, Department of Neurology, Division of Neuroinflammation and Glial Biology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5985-0822
Riley M BoveUCSF MS and Neuroinflammation Center, Weill Institute for Neurosciences, Department of Neurology, Division of Neuroinflammation and Glial Biology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2034-8800

Funding

The Role of B cells in the Origin and Progression of Multiple SclerosisR35NS111644 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEPHEN L HAUSER · 2019 to 2026
$9.1M
NINDS NIH HHS R35 NS111644
6 · The paper itself

Abstract

backgroundIn persons with multiple sclerosis (MS), the Expanded Disability Status Scale (EDSS) is the criterion standard for assessing disability, but its in-person nature constrains patient participation in research and clinical assessments.

objectiveThe aim of this study was to develop and validate a scalable, electronic, unsupervised patient-reported EDSS (ePR-EDSS) that would capture MS-related disability across the spectrum of severity.

methodsWe enrolled 136 adult MS patients, split into a preliminary testing Cohort 1 (

resultsIn Cohort 2, mean age was 50.6 years (range = 26-80) and median EDSS was 3.5 (interquartile range (IQR) = [1.5, 5.5]). The ePR-EDSS and EDSS agreed within 1-point for 86% of examinations; kappa for agreement within 1-point was 0.85 ( DISCUSSION: The ePR-EDSS was highly correlated with EDSS, with good agreement even at lower EDSS levels. For clinical care, the ePR-EDSS could enable the longitudinal monitoring of a patient's disability. For research, it provides a valid and rapid measure across the entire spectrum of disability and permits broader participation with fewer in-person assessments.

Indexed as

Multiple SclerosisAdultAgedAged, 80 and overDisability EvaluationElectronicsHumansMiddle AgedPatient Reported Outcome MeasuresdisabilityeHealthMultiple sclerosispatient-reported outcome measures

Identifiers

PMID33236967
PMCPMC8144241

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.